FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery. Barbato MI, Barone AK, Aungst SL, Miller CP, et al. Clin Cancer Res 2025;31:4412-4418.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Barbato MI, Barone AK, Aungst SL, Miller CP, et al. FDA Approval Summary: Vorasidenib for IDH-Mutant Grade 2 Astrocytoma or Oligodendroglioma Following Surgery. Clin Cancer Res 2025;31:4412-4418.
PMID: 40911439